Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) Arnaud Augert, PhD,

Slides:

Advertisements

Similar presentations

Figure 1. Figure 2 Somatic Mutation Summary A A A98-07-F009a tumor mutant reads > 10 normal mutant read = 0 tumor mutant fraction.

Advertisements

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

Sixto M. Leal, Margaret L. Gulley The Journal of Molecular Diagnostics

Volume 65, Issue 2, Pages (February 2014)

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma Maria I. Toki, MD,

Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced.

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

WT1 Promotes Invasion of NSCLC via Suppression of CDH1

Inactivation of Both FHIT and p53 Cooperate in Deregulating Proliferation-Related Pathways in Lung Cancer Francesca Andriani, PharmD, Elena Roz, MD,

DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer Yi-Chieh Yang, MS, Yen-An Tang,

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse Karinna.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

Rafal Dziadziuszko, MD, PhD, Anh T

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Volume 65, Issue 2, Pages (February 2014)

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

RET Mutation and Expression in Small-Cell Lung Cancer

Sandra Cristea, BA, Julien Sage, PhD Journal of Thoracic Oncology

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Dan Gordon Gastroenterology Volume 114, Issue 4, (April 1998)

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.

Volume 150, Issue 3, Pages (September 2018)

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer Hiroyuki.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer Alexa B. Schrock, PhD, Allison.

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients Clotilde Descarpentries, PharmD, Frédéric Leprêtre, PhD, Fabienne.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A.

Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma Jin Sung Jang, Xiaoke Wang,

Simona Coco, PhD, Anna Truini, MS, Irene Vanni, MS, Carlo Genova, MD

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 Ji-guang Zhang,

FGFR Signaling as a Target for Lung Cancer Therapy

Sandra Cristea, BA, Julien Sage, PhD Journal of Thoracic Oncology

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

MEK1 and AKT2 Mutations in Japanese Lung Cancer

Guidelines for Large-Scale Sequence-Based Complex Trait Association Studies: Lessons Learned from the NHLBI Exome Sequencing Project Paul L. Auer, Alex.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Clinicopathologic Features of Advanced Squamous NSCLC

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib Nuria Chic, MD Journal of Thoracic.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Aberrant Regulation of the MRP3 Gene in Non-small Cell Lung Carcinoma

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels

Journal of Thoracic Oncology

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome

Presentation transcript:

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) Arnaud Augert, PhD, Qing Zhang, MS, Breanna Bates, BS, Min Cui, MD, PhD, Xiaofei Wang, PhD, Gary Wildey, PhD, Afshin Dowlati, MD, David MacPherson, PhD Journal of Thoracic Oncology Volume 12, Issue 4, Pages 704-713 (April 2017) DOI: 10.1016/j.jtho.2016.12.011 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Exome analyses of human SCLC. (A) Number of protein-altering mutations in each sample, separated for missense, nonsense, insertions/deletions (indels), and essential splice site mutations. (B) Patterns of transitions and transversions in primary SCLC and in cell lines. (C) Pie charts showing mutation spectrum in selected SCLC-mutated genes. RB1, retinoblastoma gene; TP53, tumor protein p53 gene; KMT2D, lysine methyltransferase 2D gene; NOTCH1, notch 1 gene; CREBBP, CREB binding protein gene; PBRM1, polybromo 1 gene. Journal of Thoracic Oncology 2017 12, 704-713DOI: (10.1016/j.jtho.2016.12.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Candidate gene–targeted resequencing in SCLC tumors and cell lines. Oncomap showing mutations in a panel of genes chosen for targeted resequencing analysis in SCLC tumors and cell lines. TP53, tumor protein p53 gene; RB1, retinoblastoma gene; NOTCH1, notch 1 gene; KMT2C, lysine methyltransferase 2C gene; KMT2D, lysine methyltransferase 2D gene; KDM6A, lysine demethylase 6A gene; KMT2A, lysine methyltransferase 2A gene; CREBBP, CREB binding protein gene; EP300, E1A binding protein p300 gene; PBRM1, polybromo 1 gene; ARID1A, AT-rich interaction domain 1 gene; ARID1B, AT-rich interaction domain 1B gene; ARID4A, AT-rich interaction domain 4A gene; CHD7, chromodomain helicase DNA binding protein 20 gene; SETD2, SET domain containing 2 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; PTEN, phosphatase and tensin homolog gene; ELAVL2, ELAV like neuron-specific RNA protein binding 2 gene; COBL, cordon-bleu WH2 repeat protein gene; SLIT2, slit guidance ligand 2 gene; EPHA7, EPH receptor A7 gene; PTPRD, protein tyrosine phosphatase, receptor type D gene; RUNX1T1, RUNX1 translocation partner 1 gene. Journal of Thoracic Oncology 2017 12, 704-713DOI: (10.1016/j.jtho.2016.12.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Mutations in lysine methyltransferase 2D gene (KMT2D) and other chromatin regulators in SCLC. Lollipop plots showing location and type of mutations across a panel of SCLC-mutated chromatin regulating genes. Red circle indicates truncating (nonsense, frameshift, or essential splice site) mutation, and green circle indicates missense mutation. Mutations in KMT2D and polybromo 1 gene (PBRM1) shown also include Sanger sequencing–validated mutations identified through analyses of exome and RNA sequencing data. KDM6A, lysine demethylase 6A gene; ARID1A, AT-rich interaction domain 1 gene; ARID1B, AT-rich interaction domain 1B gene; CHD7, chromodomain helicase DNA binding protein 20 gene. Journal of Thoracic Oncology 2017 12, 704-713DOI: (10.1016/j.jtho.2016.12.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Mutations in lysine methyltransferase 2D gene (KMT2D) are associated with reduced lysine methyltransferase 2D protein (KMT2D) and reduced histone H3K4 monomethylation. (A) Western blot analysis showing expression of KMT2D across human SCLC cell lines that differ in KMT2D mutation status. Actin is used as a loading control. (B) Western blot analysis of extracted histones showing reduced histone H3K4 monomethylation (H3K4-1me) in the KMT2D-mutant (mut) group. Total histone H3 is used as a loading control. Quantification based on densitometry is shown to the right. A trend toward decreased H3K4 dimethylation (H3K4-2me) is also seen in the KMT2D mutants, although this was not statistically significant. p Values from Student’s t test are shown. WT, wild type; kDa, kilodalton. Journal of Thoracic Oncology 2017 12, 704-713DOI: (10.1016/j.jtho.2016.12.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions